Adjunct TG4010 for Advanced Non-Small Cell Lung Cancer (NSCLC)

TG4010 (MVA-MUC1-IL2) is a poxvirus vector that has been adapted to target MUC1, which is a major tumor-associated antigen. MVA is a highly attenuated (non-pathogenic) strain, which has been tested extensively in humans as a smallpox vaccine and is known to strongly stimulate innate and adaptive immune responses to antigens. In order to help stimulate specific T-cell responses, the sequence coding for the cytokine Interleukin 2 (IL2) is included in TG4010.

In this clinical trial of patients with advanced NSCLC and normal levels of activated natural killer cells (NK cells), combining TG4010 with chemotherapy resulted in a progression free survival rate (PFS) of 40%. Furthermore, the median survival was 17.1 mths compared with 11.3 mths for chemotherapy alone. I like this approach because TG4010 expresses the entire MUC1 gene sequence and therefore has the potential to generate an immune response to all MUC1 antigenic epitopes (the part of an antigen that is recognized by the immune system). The following is a link to upcoming TG4010 clinical trials for patients with NSCLC.
TG4010 For Patients With Advanced Non-Small Cell Lung Cancer.

Speak Your Mind